Forest Labs (FRX) Announces Phase III Study Results for Ceftaroline Achieve Primary Endpoint
Tweet Send to a Friend
Forest Laboratories, Inc. (NYSE: FRX) presented a detailed analysis of CANVAS I, a globally conducted, multi-center, Phase III clinical trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
